Figure 3.

ActRII inhibition drives skeletal muscle hypertrophy and preserves muscle mass during weight loss induced by GLP-1 receptor agonism.

A) Weights (mg) of TA, EDL, soleus, and gastrocnemius muscles isolated from HFD-fed mice treated for 14 days.

B) Percent difference in weight of TA muscles compared to control group.

C) Percent difference in weight of EDL muscles compared to control group.

D) Percent difference in weight of soleus muscles compared to control group.

E) Percent difference in weight of gastrocnemius muscles compared to control group.

F) Representative TA sections stained with H&E (20x magnification, scale bar = 100 um).

G) Quantification of average muscle fiber cross-sectional area in TA sections (n = 4: 2 images analyzed per animal, 2 animals per group).

n = 8 mice for control and semaglutide + bimagrumab groups, n = 9 mice for semaglutide and bimagrumab groups unless otherwise indicated.∗p < 0.05, ∗∗p < 0.001, ∗∗∗p < 0.0005, ∗∗∗∗p < 0.0001 for control vs. bimagrumab, semaglutide, and semaglutide + bimagrumab; #p < 0.05, ##p < 0.001, ###p < 0.0005, ####p < 0.0001 for bimagrumab vs. semaglutide and semaglutide + bimagrumab; & p < 0.05, && p < 0.001 for semaglutide vs. semaglutide + bimagrumab.